NCT03600441 - Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Follicular Lymphoma

Interventions

DRUG

Abexinostat

Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.

Trial Locations (15)

10016

Manhattan Hematology Oncology Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Clinical Research Alliance Inc, Lake Success

14004

C.H. Regional Reina Sofia, Córdoba

20014

Hospital Universitario de Donostia, Donostia / San Sebastian

28031

Hospital Universitario Infanta Leonor, Madrid

28229

Hospital del Mar, Barcelona

40207

Norton Cancer Institute - St. Matthews Campus, Louisville

60068

Advocate Medical Group - Park Ridge, Luther Lane - Oncology, Park Ridge

66046

Centre Hospitalier de Perpignan, Perpignan

76012

Arlington Cancer Center, Arlington

76504

Central Texas Veterans Health Care System - NAVREF, Temple

98506

Vista Oncology Inc. PS, Olympia

15224-2156

Bone Marrow Transplant Hematology Oncology Associates, Pittsburgh

08035

Hospital Universitario Vall d'Hebrón, Barcelona

All Listed Sponsors

lead

Xynomic Pharmaceuticals, Inc.

INDUSTRY